Krystal Biotech, Inc. - Form 8-K Summary
Business Context and Reporting Period
Krystal Biotech, Inc., a Delaware corporation, filed this Current Report on Form 8-K on November 1, 2017, regarding an event reported on that date. The transaction closed on November 2, 2017.
Key Financial Metrics
This filing reports a specific equity transaction rather than comprehensive financial statements. Key metrics related to the transaction include:
- Shares Issued: 70,000 shares of common stock.
- Price Per Share: $11.00.
- Aggregate Gross Proceeds: $770,000.00.
- Registration Status: Unregistered sale exempt under Rule 506 of Regulation D and Section 4(a)(2) of the Securities Act of 1933.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity outside of the proceeds from this specific transaction.
Material Changes
The material change reported is the issuance of new equity to two nonprofit purchasers: the Epidermolysis Bullosa Medical Research Foundation (EBMRF) and EB Research Partnership, Inc. (EBRP). This transaction increases the company's share count and cash position by the amount of gross proceeds.
Outlook, Risks, and Restrictions
The purchasers have agreed to acquire the securities for investment purposes only. The shares are subject to a six-month lock-up period, restricting the purchasers from selling, transferring, or disposing of the shares during that time. Appropriate legends will be affixed to the securities.
Investor Verification Checklist
- Confirm the closing date of November 2, 2017, and the receipt of $770,000 in gross proceeds.
- Verify the identity of the purchasers (EBMRF and EBRP) and their nonprofit status.
- Review the six-month lock-up agreement terms restricting the resale of the 70,000 shares.
- Check subsequent filings for the impact of this capital raise on the company's cash runway and operational milestones.